Important Reminder for REGENXBIO Investors on Class Action Deadline Approaching Soon
Investors in REGENXBIO Inc. (NASDAQ: RGNX) are reminded of an essential upcoming deadline for participating in a federal securities class action. The deadline to file for lead plaintiff status in this case is set for April 14, 2026. This information comes courtesy of Faruqi & Faruqi, LLP, a reputable national law firm specializing in securities litigation.
The firm is actively investigating potential claims on behalf of individuals who acquired REGENXBIO shares between February 9, 2022, and January 27, 2026, and experienced losses during this period. The reason behind this investigation stems from allegations that REGENXBIO and its executives engaged in misleading statements regarding the safety and effectiveness of its RGX-111 trial, which is aimed at treating MPS I, also known as Hurler syndrome.
In a notable press release dated January 28, 2026, the company disclosed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on RGX-111 due to concerns raised by a preliminary analysis of a single case of a neoplasm found in a Phase I/II study participant. Notably, this decision also impacted RGX-121, designed for MPS II, due to shared risks inherent to both studies. Following this disclosure, REGENXBIO's stock price plummeted by $2.40, a significant decline of 17.9%, closing at $11.01 per share.
Faruqi & Faruqi encourages affected investors to reach out and discuss possible legal routes, including the option of joining the class action or seeking individual remedies. Interested parties can contact Senior Partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information. Furthermore, the firm is open to insights from anyone with knowledge regarding REGENXBIO’s activities, which could be vital for the ongoing litigation. Additionally, individuals can visit Faruqi & Faruqi's dedicated webpage for this class action at www.faruqilaw.com/RGNX to stay updated.
Participating as a lead plaintiff has its own set of benefits, including potentially having significant influence over the pace and direction of the litigation. Yet, any current shareholders who are not inclined to take up this role can still needlessly remain as absent class members, with their rights to recovery intact irrespective of their decision.
With hundreds of millions of dollars successfully recovered for investors since its inception in 1995, Faruqi & Faruqi continues its tradition of fighting for the rights of shareholders affected by fraudulent corporate behavior. Investors are urged to be proactive in assessing their options as this looming deadline approaches.
For further updates on this ongoing situation, the firm is available on professional networks such as LinkedIn and X, or you can follow their updates on Facebook. Please note that this announcement is to be treated as informational and does not serve as legal advice; all communications will remain confidential. Investors are encouraged to seek counsel tailored to their individual circumstances, as outcomes of previous cases do not guarantee similar results in new matters.
The firm is actively investigating potential claims on behalf of individuals who acquired REGENXBIO shares between February 9, 2022, and January 27, 2026, and experienced losses during this period. The reason behind this investigation stems from allegations that REGENXBIO and its executives engaged in misleading statements regarding the safety and effectiveness of its RGX-111 trial, which is aimed at treating MPS I, also known as Hurler syndrome.
In a notable press release dated January 28, 2026, the company disclosed that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on RGX-111 due to concerns raised by a preliminary analysis of a single case of a neoplasm found in a Phase I/II study participant. Notably, this decision also impacted RGX-121, designed for MPS II, due to shared risks inherent to both studies. Following this disclosure, REGENXBIO's stock price plummeted by $2.40, a significant decline of 17.9%, closing at $11.01 per share.
Faruqi & Faruqi encourages affected investors to reach out and discuss possible legal routes, including the option of joining the class action or seeking individual remedies. Interested parties can contact Senior Partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information. Furthermore, the firm is open to insights from anyone with knowledge regarding REGENXBIO’s activities, which could be vital for the ongoing litigation. Additionally, individuals can visit Faruqi & Faruqi's dedicated webpage for this class action at www.faruqilaw.com/RGNX to stay updated.
Participating as a lead plaintiff has its own set of benefits, including potentially having significant influence over the pace and direction of the litigation. Yet, any current shareholders who are not inclined to take up this role can still needlessly remain as absent class members, with their rights to recovery intact irrespective of their decision.
With hundreds of millions of dollars successfully recovered for investors since its inception in 1995, Faruqi & Faruqi continues its tradition of fighting for the rights of shareholders affected by fraudulent corporate behavior. Investors are urged to be proactive in assessing their options as this looming deadline approaches.
For further updates on this ongoing situation, the firm is available on professional networks such as LinkedIn and X, or you can follow their updates on Facebook. Please note that this announcement is to be treated as informational and does not serve as legal advice; all communications will remain confidential. Investors are encouraged to seek counsel tailored to their individual circumstances, as outcomes of previous cases do not guarantee similar results in new matters.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.